Sai Life Sciences Limited Receives GST Order with Demand of INR 16.28 Crores Plus Interest and Penalty
Sai Life Sciences Limited disclosed receipt of a GST order dated 29 April 2026 with demand of INR 16,28,46,397, interest of INR 13,31,50,353, and penalty of INR 3,25,69,279 related to financial year 2021-22. The company plans to appeal and expects no material financial impact.

*this image is generated using AI for illustrative purposes only.
Sai Life Sciences Limited has informed the stock exchanges about receipt of a Goods and Services Tax (GST) order from the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi. The order was passed on 29 April 2026 at 11:32 AM under Section 107 (11) of the Central Goods and Services Tax Act, 2017 and the Karnataka Goods and Services Tax Act, 2017.
Details of the GST Order
The order raises a demand concerning alleged excess availment of input tax credit in GSTR-3B than available in GSTR-2A for the financial year 2021-22. The tax authority has specified the following amounts:
| Component | Amount (INR) |
|---|---|
| IGST Demand | 16,28,46,397 |
| Interest | 13,31,50,353 |
| Penalty | 3,25,69,279 |
Company's Response
According to the disclosure made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sai Life Sciences Limited stated that based on its assessment, an appeal will be filed against the order. The company expressed hope for a favourable outcome at the Tribunal level and indicated that it does not reasonably expect the said order to have any material financial impact on its operations.
The disclosure was signed by Runa Karan, Company Secretary & Compliance Officer, and submitted to both the National Stock Exchange of India Limited and BSE Limited on 30 April 2026.
Historical Stock Returns for Sai Life Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.36% | +6.31% | +8.48% | +16.66% | +49.72% | +39.86% |
How might this GST dispute affect Sai Life Sciences' credit rating and access to financing during the appellate process?
What potential impact could this case have on GST compliance practices across the pharmaceutical industry?
Will Sai Life Sciences need to provide bank guarantees or deposits while appealing, and how might this affect their working capital?


































